2,6-Dioxaspiro[4,5]decane Opioid Agonists for Gi-Biased Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid receptor agonists, such as morphine, cause significant side effects like respiratory depression and constipation due to activation of both Gi and β-arrestin signaling pathways, limiting their clinical efficacy and safety.
Innovation Solution
Development of Gi protein-biased μ-receptor agonists, specifically 2,6-dioxaspiro[4,5]decane compounds represented by formula (I) or their pharmaceutically acceptable salts, which selectively activate the Gi signaling pathway with minimal effect on the β-arrestin pathway, reducing adverse reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional opioid agonists like morphine are used, then analgesic effect is achieved, but side effects such as respiratory depression and constipation occur due to activation of both Gi and β-arrestin signaling pathways
Solution Approach 1:
The patent segments the signaling pathway activation by designing compounds that selectively activate the Gi pathway while avoiding β-arrestin pathway activation. This is achieved through specific molecular structure modifications in the 2,6-dioxaspiro[4,5]decane compound series, creating a functional separation of signaling outcomes.
Solution Approach 2:
The invention applies local quality by modifying specific regions of the opioid receptor ligand structure (the 2,6-dioxaspiro[4,5]decane core with specific substituents) to create localized interactions that favor Gi pathway activation. The molecular structure is optimized at specific positions to achieve selective signaling pathway engagement.
2Object-generated harmful factors
If Gi protein-biased μ-receptor agonists are developed, then side effects are reduced, but the complexity of achieving selective pathway activation increases
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular parameters (substituent types, positions, and configurations on the 2,6-dioxaspiro[4,5]decane core) to optimize selectivity for the Gi pathway. This involves adjusting chemical parameters to achieve the desired signaling bias while managing structural complexity.
Data Source
AI summary
The present invention relates to a series of 2,6-dioxaspiro [4,5] decane derivatives and applications thereof in preparation of opiate receptor μ agonist related drugs; and in particular relates to the derivative compounds shown in formula (I), tautomers thereof or pharmaceutically acceptable compositions thereof.